Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NiKem Research SRL

www.nikemresearch.com

Latest From NiKem Research SRL

NiKem gets GLP certification

The Italian government has certified NiKem Research's bioanalysis facilities, allowing it to support its clients' preclinical pharmacokinetics and toxicology studies. The company was already offering hit validation and multiparametric lead optimisation services, along with other services related to drug discovery.

New Approaches to Neuropathic Pain

In some ways, neuropathic pain seems an odd choice of focus for a small start-up. It comes in many forms and its mechanisms are poorly understood. Moreover, the size and strength of those with stakes in the pain market might be another reason for emerging companies to steer clear. Fortunately, they're not. The unmet need is huge: Only one in two patients actually get some relief from existing drugs, in part because their mechanisms of action are fairly generalized. There remains plenty to be done in identifying and understanding the precise mechanisms behind the various flavors of neuropathic pain. For those whocan figure out new approaches to pain or new uses in pain for failed or overlooked compounds -- the companies profiled in this issue are doing both -- there's a big reward at the end: Sales of neuropathic pain therapies in the seven major pharmaceutical markets reached nearly $5 billion in 2007.
BioPharmaceutical

Deals Shaping the Medical Industry (7/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Brane's Brain R&D Spun Out, Seeks Funding

Nikem spun out its R&D assets with about a years' worth of funds to pursue development of its neuropathic pain and Parkinson's disease compounds, which are currently in preclinical development. The company, Brane, is seeking Series A funding.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Italy
  • Parent & Subsidiaries
  • NiKem Research SRL
  • Senior Management
  • Giuseppe Giardina, CEO
  • Contact Info
  • NiKem Research SRL
    Phone: (39) 02 356941
    Via Zambeletti 25
    Milan, 20021
    Italy
Advertisement
Advertisement
UsernamePublicRestriction

Register